Spain Pharmaceuticals and Healthcare Report - Business Monitor International - Industry Reports

Spain Pharmaceuticals and Healthcare Report

Spain Pharmaceuticals and Healthcare Report - Business Monitor International - Industry Reports
Spain Pharmaceuticals and Healthcare Report
Published Oct 22, 2016
83 pages — Published Oct 22, 2016
Price US$ 1,295.00  |  Buy this Report Now

About This Report

  
Abstract:

In September ----, German healthcare company Fresenius agreed a EUR-.-bn (USD-.-bn) leveraged buy-out for Spain s largest private hospital operator Quironsalud, expecting the transaction to be completed by early ----. ...leveraged buy-out for Spain s largest private hospital operator Quironsalud, expecting the transaction to be completed by early ----. In August ----, Orexigen Therapeutics Ireland and Laboratorios Farmaceuticos Rovi executed a commercialisation and distributorship agreement for Mysimba (naltrexone HCl /bupropion HCl prolonged release) in Spain. In July ----, Funds advised by Apax Partners entered into a definitive agreement to acquire the operating subsidiaries of Invent Farma, a Spanish pharmaceutical company, from a consortium of investors led by ...In August ----, Orexigen Therapeutics Ireland and Laboratorios Farmaceuticos Rovi executed a commercialisation and distributorship agreement for Mysimba (naltrexone HCl /bupropion HCl prolonged release) in Spain. In July ----, Funds advised by Apax Partners entered into a definitive agreement to acquire the operating subsidiaries of Invent Farma, a Spanish pharmaceutical company, from a consortium of investors led by

...In our Pharmaceutical Risk/Reward Index for Q---, Spain scored --.- and ranked --th out of the -- countries surveyed in Western Europe - just below the Netherlands (--.-). While Spain offers investors positive features, such as its large drug market (Market Expenditure score of --.- out of --) and a high pensionable population (score of -.- out of -), it also has problems, such as the government s focus on cost containment, low population growth (score of -.- out of -), cumbersome bureaucracy and provincial differences regarding drug regulations and reimbursement. ...

...BMI View: Growth in the Spanish pharmaceutical market will remain sluggish in the coming years. Despite returning to growth in ----, the market is unlikely to recover to its ---- peak value until ----. ...Despite returning to growth in ----, the market is unlikely to recover to its ---- peak value until ----. An aging population and a high chronic disease burden will drive demand for patented medicines, which account for the vast majority of the total market. Implementation of further drug price caps across the pharmaceutical sector as the government looks to contain spiralling healthcare cost, pose downside risks to our forecast. ...An aging population and a high chronic disease burden will drive demand for patented medicines, which account for the vast majority of the total market. Implementation of further drug price caps across the pharmaceutical sector as the government looks to contain spiralling healthcare cost, pose downside risks to our forecast.

...

  
Source:
Document ID
1748-2216
Country
Industry
Format:
PDF Adobe Acrobat
Buy Now

Business Monitor International - Industry Reports—Established in 1984, Business Monitor International is a leading online publisher of specialist business information on global emerging markets. Business Monitor's range of quarterly services covers political risk, finance, macroeconomic performance, outlook and forecast, industry sectors and the business operating environment. Each Industry Report has been researched at source, and features latest-available data covering production, sales, imports and exports; 5-year industry forecasts through end-2012; company rankings and competitive landscapes for multinational and local manufacturers and suppliers; and analysis of latest industry developments, trends and regulatory changes.

About the Author


Cite this Report

  
MLA:
Business Monitor International - Industry Reports. "Spain Pharmaceuticals and Healthcare Report" Oct 22, 2016. Alacra Store. Dec 07, 2016. <http://www.alacrastore.com/storecontent/Business-Monitor-International-Industry-Reports/Spain-Pharmaceuticals-and-Healthcare-Report-2026-302>
  
APA:
Business Monitor International - Industry Reports. (2016). Spain Pharmaceuticals and Healthcare Report Oct 22, 2016. New York, NY: Alacra Store. Retrieved Dec 07, 2016 from <http://www.alacrastore.com/storecontent/Business-Monitor-International-Industry-Reports/Spain-Pharmaceuticals-and-Healthcare-Report-2026-302>
  
US$ 1,295.00
$  £  
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.